PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

@article{Kim2011PAM1616AS,
  title={PAM-1616, a selective peroxisome proliferator-activated receptor $\gamma$ modulator with preserved anti-diabetic efficacy and reduced adverse effects.},
  author={Mi-kyung Kim and Yu Na Chae and Song-hyen Choi and Ho Sang Moon and Moon Ho Son and M H Bae and Hyun Ho Choi and Youn Hur and Eunkyung Kim and Yoo Hoi Park and Chan Sun Park and Jae Gyu Kim and Joong Inn Lim and Chang-Yell Shin},
  journal={European journal of pharmacology},
  year={2011},
  volume={650 2-3},
  pages={
          673-81
        }
}

Figures and Tables from this paper

Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)
TLDR
Recent (2008–present) patent applications concerning PPAR ligands claimed for the use in metabolic disorders as well as patents indicating new applications for modulators of the PPAR subtypes are summarized.
Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
TLDR
Clinical trial design and population might have obscured beneficial activities and, in addition, synergistic multi-target approaches as well as selective PPAR modulators could generate safer approaches with higher therapeutic efficacy.
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty
TLDR
The apparent disparity between effects on laboratory measurements and clinical outcomes may be related to limitations of clinical trials, adverse effects of PPAR-γ activation, or off-target effects of thiazolidinedione agents.
A Novel Partial PPARγ Agonist Has Weaker Lipogenic Effect in Adipocytes and Stimulates GLUT4 Translocation in Skeletal Muscle Cells via AMPK-Dependent Signaling
TLDR
GS2 may be a promising therapeutic agent for the treatment of insulin resistance and type 2 diabetes mellitus without adiposity and significantly stimulated GLUT4 translocation to the plasma membrane in a dose-dependent manner via the AMPK-dependent signaling pathway in skeletal muscle cells.
Multitargeted bioactive ligands for PPARs discovered in the last decade
TLDR
This review updated and generalized the development of PPARγ partial agonist rosiglitazone,PPARγ antagonists, PPARα/γ dual agonists, PP ARδ partial agonists), PPARδ antagonists,PParα/δ dual agonist, PParγ/ Δ dual agonism, and PPAR α/γ/ δ pan‐agonists published in recent decade.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  • 2020
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
TLDR
Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension, via its partial PPARγ-agonistic activity.
Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
TLDR
It is argued that partial/submaximal activation of PPARγ could be a major target for vascular endothelial functional improvement and the vascular protective properties of pharmacological agents, which submaximally activate PParγ, should be investigated.
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties*
TLDR
MCC-555 is characterized, a novel thiazolidinedione ligand for PPARγ with unique functional properties and the antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity forPPARγ is less than 1 10 that of BRL 49653.
A Selective Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Modulator Blocks Adipocyte Differentiation but Stimulates Glucose Uptake in 3T3-L1 Adipocytes
TLDR
A novel PParγ ligand is identified that does not activate PPARγ but selectively and competitively blocks thiazolidinedione-induced PPAR� activation and adipocyte conversion and antagonizes target gene activation as well as repression in agonist-treated 3T3-L1 adipocytes.
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.
TLDR
The clinical consequences of PPARgamma polymorphisms in humans, as well as several studies in mice using general or tissue-specific knockout techniques, are reviewed, allowing us to hypothesize a general mechanism of PPargamma action and speculate on future trends in the use of PP ARgamma as a target in the treatment of type II diabetes.
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
TLDR
It is established that novel selective PPARgamma modulators can produce altered receptor conformational stability leading to distinctive gene expression profiles, reduced adipogenic cellular effects, and potentially improved in vivo biological responses.
A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
TLDR
A novel PPargamma ligand is identified that does not activate PPARgamma but selectively and competitively blocks thiazolidinedione-induced PPARGamma activation and adipocyte conversion and antagonizes target gene activation as well as repression in agonist-treated 3T3-L1 adipocytes.
Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity
TLDR
The data establish halofenate as a novel SPPARγM with promising therapeutic utility with the potential for less weight gain.
L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ
TLDR
A novel non-TZD ligand for PPARγ is shown to be a potent and first known partial agonist for this receptor and a critical functional role for Cys313, and helix 3, in contributing to ligand binding and subsequent agonist-induced conformational changes is suggested.
...
1
2
3
4
5
...